Lenalidomid Alkaloid-Int (Lenalidomide)

Lenalidomide is employed in hematologic malignancies and related myelodysplastic conditions.

• Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease.
• Mantle cell lymphoma: induces tumor regression and prolongs remission when combined with standard chemotherapy.
• Myelodysplastic syndromes with 5q deletion: corrects ineffective hematopoiesis and reduces transfusion dependence.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This interaction promotes ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). The resulting loss of these factors leads to anti‑angiogenic activity, modulation of cytokine production, enhanced natural‑killer‑cell‑mediated cytotoxicity, direct inhibition of malignant plasma‑cell proliferation, and tumor microenvironment remodeling.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue
• Diarrhea
• Rash
• Constipation

Serious or Rare Side Effects

• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism
• Severe neutropenia or leukopenia
• Teratogenic effects leading to fetal harm

Key precautions should be observed when prescribing lenalidomide to minimize risks.

• Pregnancy: contraindicated; category X, avoid use in pregnant women.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Hematologic monitoring: perform regular CBC to detect neutropenia or anemia.
• Renal impairment: adjust therapy and monitor renal function.
• Drug interactions: avoid concomitant use with strong CYP3A4 inducers without supervision.
• Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Lenalidomide can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure.
• Anticoagulants (warfarin): increased risk of bleeding when combined with lenalidomide.
• Immunosuppressants (e.g., cyclosporine): heightened risk of severe cytopenias.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels.
• NSAIDs: may exacerbate thrombocytopenia.
• Hormonal contraceptives: reduced efficacy, advise alternative non‑hormonal methods.